# Safety, Tolerability and Pharmacokinetics of Y-2(Edaravone And Borneol) Sublingual Tablet

> **NCT03495206** · PHASE1 · UNKNOWN · sponsor: **Yantai YenePharma Co., Ltd.** · enrollment: 24 (estimated)

## Conditions studied

- Stroke, Acute
- Intracranial Hemorrhages

## Interventions

- **DRUG:** Y-2(Edaravone And Borneol) Sublingual Tablet

## Key facts

- **NCT ID:** NCT03495206
- **Lead sponsor:** Yantai YenePharma Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2018-10-25
- **Primary completion:** 2020-12
- **Final completion:** 2021-02
- **Target enrollment:** 24 (ESTIMATED)
- **Last updated:** 2020-02-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03495206

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03495206, "Safety, Tolerability and Pharmacokinetics of Y-2(Edaravone And Borneol) Sublingual Tablet". Retrieved via AI Analytics 2026-05-30 from https://api.ai-analytics.org/clinical/NCT03495206. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*